ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO438

Immunosuppressive Treatment in Children with IgA Nephropathy and Evidence to Support the Clinical Value of Podocytopathic Features

Session Information

  • Pediatric Nephrology - II
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology


  • Alexandra, Cambier, Robert Debré hospital, Paris, France
  • Rabant, Marion, NECKER Hospital, PARIS, France
  • Peuchmaur, Michel, APHP Université Diderot Paris7, Paris, France
  • Hertig, Alexandre, Sorbonne University, Paris, France
  • Deschênes, Georges, Hospital Robert Debre/Pediatric Nephrology, Paris, France
  • Salomon, Remi, hopital Necker, PARIS, France
  • Hogan, Julien, Emory University, Atlanta, Georgia, United States
  • Robert, Thomas, Assistance Publique des Hôpitaux de Marseille, Marseille, France

There is a need for treatment guidelines and prognostic factor identification in children with primary IgA nephropathy (IgAN). We analyzed the causative effect of steroids and the applicability of the Oxford classification


Data on 82 consecutive children (mean 10.6 years; median follow-up 3.3 years) were reviewed. 21 patients (25.6%) presented with acute kidney injury, and 6 (7.3%) with nephrotic syndrome. Renal biopsies were scored for Oxford classification, podocytopathic features, and extracapillary proliferation in two groups: a groupG1, treated with steroid therapy (later in association with cyclophosphamide) and supportive care (renin angiotensin system blockade) and a group treated by supportive care alone.


The two groups were not comparable, since baseline clinical data were different. eGFR in immunosupressive group significantly improved between M0 and M6 from 89.9 (61.2–114.5) to 111.7 (101.7–120)ml/min/1.73m2, p=0.001). Proteinuria also significantly decreased from (1.6 (1–4.3) to 0.3 (0.2–0.7)g/g creat, p<0.001). In the supportive care group group, eGFR and proteinuria remained stable. Podocytopathic features were predictive of renal function decline by univariable (-4.9±14.9ml/min/1.73m2, p=0.0079) and multivariable analysis and of poor renal prognosis to a combined event (renal function impairment more than 10% of the eGFR baseline or chronic kidney disease stage 3 at 6 months) in univariable and multivariable analysis. MEST-C score failed to prove its prognostic value.


Immunosuppressive treatment, especially steroid therapy, seems beneficial in children with glomerular inflammation and proliferation. The Oxford classification does not appear to be entirely appropriate in predicting long-term renal prognosis for children, whereas the characteristics of podocytopathy are strongly predictive of renal prognosis.